N-isopentyladenosine manufacturers
|
| | N-isopentyladenosine Basic information |
| Product Name: | N-isopentyladenosine | | Synonyms: | N-isopentyladenosine;N-(3-Methylbutyl)adenosine;Adenosine, N-(3-methylbutyl)-;Einecs 241-638-1;N-(3-Methylbutyl)adenosine, N6-Isoamyladenosine;N6-(3-Methylbutyl)adenosine;(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(isopentylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol;N6-Isoamyladenosine | | CAS: | 17659-78-8 | | MF: | C15H23N5O4 | | MW: | 337.37 | | EINECS: | 241-638-1 | | Product Categories: | | | Mol File: | 17659-78-8.mol |  |
| | N-isopentyladenosine Chemical Properties |
| Boiling point | 632.9±65.0 °C(Predicted) | | density | 1.57 | | pka | 13.12±0.70(Predicted) |
| | N-isopentyladenosine Usage And Synthesis |
| Uses | N-(3-Methylbutyl)adenosine is an adenosine analog. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. Its popular products are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277)[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26(6):1490-1500. DOI:10.1016/j.drudis.2021.02.020 |
| | N-isopentyladenosine Preparation Products And Raw materials |
|